Blueprint Medicines - BPMC Stock Forecast, Price & News

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last year. There are currently 2 sell ratings, 3 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BPMC shares.
View BPMC analyst ratings or view top-rated stocks.

14 brokers have issued 1 year target prices for Blueprint Medicines' shares. Their BPMC share price forecasts range from $40.00 to $152.00. On average, they anticipate the company's stock price to reach $92.06 in the next twelve months. This suggests a possible upside of 38.6% from the stock's current price.
View analysts price targets for BPMC or view top-rated stocks among Wall Street analysts.

Blueprint Medicines' stock was trading at $107.11 on January 1st, 2022. Since then, BPMC shares have decreased by 38.0% and is now trading at $66.42.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our BPMC earnings forecast.

Blueprint Medicines Co. (NASDAQ:BPMC) posted its quarterly earnings results on Tuesday, August, 2nd. The biotechnology company reported ($2.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.23) by $0.45. The biotechnology company had revenue of $36.55 million for the quarter, compared to analyst estimates of $37.61 million. Blueprint Medicines had a negative trailing twelve-month return on equity of 45.89% and a negative net margin of 304.41%. The firm's revenue was up 33.9% compared to the same quarter last year. During the same quarter last year, the company earned ($1.86) EPS.

Blueprint Medicines issued an update on its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $180.00 million-$200.00 million, compared to the consensus revenue estimate of $194.85 million.

16 employees have rated Blueprint Medicines Chief Executive Officer Kate Haviland on Glassdoor.com. Kate Haviland has an approval rating of 100% among the company's employees. This puts Kate Haviland in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at Blueprint Medicines to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), QUALCOMM (QCOM), Amarin (AMRN), CRISPR Therapeutics (CRSP) and Nektar Therapeutics (NKTR).

(BPMC) raised $115 million in an IPO on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC."

Shares of BPMC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BPMC stock can currently be purchased for approximately $66.42.

Blueprint Medicines (NASDAQ:BPMC) has a market capitalization of $3.96 billion and generates $180.08 million in revenue each year. The biotechnology company earns $-644,090,000.00 in net income (profit) each year or ($11.87) on an earnings per share basis.

The company employs 495 workers across the globe.

Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.blueprintmedicines.com. The biotechnology company can be reached via phone at (617) 374-7580 or via email at ir@blueprintmedicines.com.